




RealRate

PHARMACEUTICAL 2023

DMK Pharmaceuticals Corp
Rank 426 of 471



The relative strengths and weaknesses of DMK Pharmaceuticals Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of DMK Pharmaceuticals Corp compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 5.9% points. The greatest weakness of DMK Pharmaceuticals Corp is the variable Stockholders Equity, reducing the Economic Capital Ratio by 114% points.

The company's Economic Capital Ratio, given in the ranking table, is 86%, being 158% points below the market average of 245%.

Input Variable	Value in 1000 USD
Assets, Current	9,272
Cost of Goods Sold	6,187
Intangible Assets	0
Liabilities, Current	11,396
Liabilities, Non-Current	0
Other Assets	370
Other Compr. Net Income	0
Other Expenses	2.0
Other Liabilities	186
Other Net Income	-1,417
Other Revenues	4,756
Property and Equipment	1,289
Research and Development	10,380
Selling, General and Administrative Expense	13,248

Output Variable	Value in 1000 USD
Assets	10,931
Liabilities	11,582
Expenses	29,817
Revenues	4,756
Stockholders Equity	-651
Net Income	-26,478
Comprehensive Net Income	-26,478
BaseVar	29,251
ECR before LimitedLiability	-248%
Economic Capital Ratio	86%